Litcius/Paper detail

Baricitinib: the first immunomodulatory treatment to reduce COVID-19 mortality in a placebo-controlled trial

Andre C Kalil, Justin Stebbing

2021The Lancet Respiratory Medicine38 citationsDOIOpen Access PDF

Topics & Concepts

MedicineMEDLINEIntensive care medicineInternal medicineClinical trialEmergency medicineRandomized controlled trialMortality rateDiseaseRisk assessmentSepsis Diagnosis and TreatmentCOVID-19 Clinical Research StudiesClostridium difficile and Clostridium perfringens research
Baricitinib: the first immunomodulatory treatment to reduce COVID-19 mortality in a placebo-controlled trial | Litcius